Antitumor Activity and Pharmacokinetics of TAS‐106, l‐(3‐C‐Ethynyl‐β‐D‐ribo‐pentofuranosyl)cytosine

類似資料

• Cellular and Biochemical Mechanisms of the Resistance of Human Cancer Cells to a New Anticancer Ribo‐nucleoside, TAS‐106
  著者:: Shimamoto, Yuji, 等
  出版事項: (2002)
• A nucleoside anticancer drug, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression
  著者:: Meike, Shunsuke, 等
  出版事項: (2011)
• Sensitivity of Human Cancer Cells to the New Anticancer Ribo‐nucleoside TAS–106 Is Correlated with Expression of Uridine‐cytidine Kinase 2
  著者:: Shimamoto, Yuji, 等
  出版事項: (2002)
• A Nucleoside Anticancer Drug, 1-(3-C-Ethynyl-β-D-Ribo-Pentofuranosyl)Cytosine, Induces Depth-Dependent Enhancement of Tumor Cell Death in Spread-Out Bragg Peak (SOBP) of Proton Beam
  著者:: Maeda, Kenichiro, 等
  出版事項: (2016)
• Antitumor Activity of BOF‐A2, a New 5‐Fluorouracil Derivative
  著者:: Fujii, Setsuro, 等
  出版事項: (1989)